Literature DB >> 1966428

Monoclonal antibody-selected variants of MHV-4 contain substitutions and deletions in the E2 spike glycoprotein.

T M Gallagher1, M J Buchmeier.   

Abstract

Selection and analysis of MHV-4 (strain JHM) variants resistant to E2-specific neutralizing MAbs was performed. Two types of variation in the E2 spike glycoprotein were found. From minimally passaged stocks of MHV-4, putative point mutants were obtained. These mutants were resistant only to the MAb used to select them. In contrast, multiply passaged stocks were found to harbor variants uniformly resistant to two selecting MAbs. Northern and Western blot analysis of the viral RNAs and proteins synthesized by these doubly-resistant variants showed that they contained large deletions in both mRNA 3 and its E2 translation product, localized to a 15 kilodalton region within the amino terminal 90B post-translational fragment. The selective advantage of this second class of variants lacking sequences within E2 90B was a result of their reduced cytopathology, thereby allowing cultures to support virus production for prolonged periods.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1966428     DOI: 10.1007/978-1-4684-5823-7_53

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  The nsp1, nsp13, and M proteins contribute to the hepatotropism of murine coronavirus JHM.WU.

Authors:  Rong Zhang; Yize Li; Timothy J Cowley; Adam D Steinbrenner; Judith M Phillips; Boyd L Yount; Ralph S Baric; Susan R Weiss
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

Review 2.  Viral mouse models used to study multiple sclerosis: past and present.

Authors:  J E Libbey; R S Fujinami
Journal:  Arch Virol       Date:  2021-02-13       Impact factor: 2.685

3.  Distinct Roles for Sialoside and Protein Receptors in Coronavirus Infection.

Authors:  Enya Qing; Michael Hantak; Stanley Perlman; Tom Gallagher
Journal:  mBio       Date:  2020-02-11       Impact factor: 7.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.